Description

CMX-2043 (CAS 910627-26-8) is a novel ?-lipoic acid analogue developed to enhance antioxidant properties and activate key cell survival pathways. Synthesized under GMP conditions, it boasts a purity of ?99.42%, ensuring high-quality standards for laboratory applications.

In vitro studies have shown that CMX-2043 is more effective than ?-lipoic acid in antioxidant activity and in activating insulin receptor kinase, soluble tyrosine kinase, and Akt phosphorylation. These mechanisms contribute to its cytoprotective effects, particularly in models of ischemia-reperfusion injury.

Research indicates that CMX-2043 may offer therapeutic potential in conditions involving oxidative stress and cellular injury, such as ischemic heart disease and traumatic brain injury.

This compound is intended strictly for laboratory research use and is not approved for human or veterinary use.

Product Specifications

Mechanism of Action & Research Applications

CMX-2043 functions by enhancing antioxidant defenses and activating key cell survival pathways. It has been shown to activate insulin receptor kinase, soluble tyrosine kinase, and Akt phosphorylation, leading to cytoprotective effects in various models of cellular injury.

In laboratory research, CMX-2043 is utilized to investigate its efficacy in conditions involving oxidative stress and cellular injury, such as ischemia-reperfusion injury and traumatic brain injury.

Disclaimer

This product is intended strictly for laboratory research use only. It is not approved for human or veterinary use. Handle according to institutional safety protocols.